Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.98 Million EUR | -131.28% |
| 2022 | 33.53 Million USD | -29.97% |
| 2021 | 46.56 Million EUR | -49.45% |
| 2020 | 54.38 Million EUR | 22.14% |
| 2019 | 64.27 Million EUR | 47.92% |
| 2018 | 19.1 Million EUR | 228.05% |
| 2017 | -35.15 Million EUR | -185.48% |
| 2016 | -10.71 Million EUR | 5.43% |
| 2015 | -14.74 Million EUR | -496.72% |
| 2014 | 3.71 Million EUR | 123.48% |
| 2013 | -15.83 Million EUR | 39.02% |
| 2012 | -25.96 Million EUR | -7.59% |
| 2011 | -22.85 Million EUR | 48.05% |
| 2010 | -46.45 Million EUR | -39.53% |
| 2009 | -33.29 Million EUR | 1.19% |
| 2008 | -15.26 Million EUR | 29.65% |
| 2007 | -27.81 Million EUR | -131.34% |
| 2006 | -14.91 Million EUR | -4.23% |
| 2005 | -19.86 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.14 Million USD | -240.23% |
| 2024 Q2 | 1.91 Million EUR | 55.51% |
| 2024 Q3 | 7.25 Million USD | 269.35% |
| 2023 Q3 | 7.86 Million USD | 16.94% |
| 2023 Q2 | 6.72 Million USD | 158.08% |
| 2023 Q4 | 6.86 Million USD | -12.64% |
| 2023 FY | - EUR | -131.28% |
| 2023 Q1 | -11.57 Million USD | 2.27% |
| 2022 Q4 | -11.84 Million USD | -194.88% |
| 2022 FY | - USD | -29.97% |
| 2022 Q1 | 7.8 Million USD | -43.87% |
| 2022 Q2 | 22.98 Million USD | 194.54% |
| 2022 Q3 | 12.48 Million USD | -45.69% |
| 2021 Q1 | 15.92 Million EUR | -36.74% |
| 2021 Q3 | 4.48 Million EUR | -59.8% |
| 2021 Q4 | 13.89 Million EUR | 209.72% |
| 2021 FY | - EUR | -49.45% |
| 2021 Q2 | 11.16 Million EUR | -29.91% |
| 2020 Q4 | 25.17 Million EUR | -17.77% |
| 2020 Q2 | 12.56 Million EUR | -47.09% |
| 2020 Q3 | 30.61 Million EUR | 143.67% |
| 2020 Q1 | 23.75 Million EUR | 9.89% |
| 2020 FY | - EUR | 22.14% |
| 2019 Q4 | 21.61 Million EUR | -0.4% |
| 2019 FY | - EUR | 47.92% |
| 2019 Q1 | 15.3 Million EUR | 42.69% |
| 2019 Q2 | 16.79 Million EUR | 9.78% |
| 2019 Q3 | 21.7 Million EUR | 29.2% |
| 2018 FY | - EUR | 228.05% |
| 2018 Q3 | 20.3 Million EUR | 171.31% |
| 2018 Q2 | 7.48 Million EUR | -39.94% |
| 2018 Q1 | 12.46 Million EUR | 116.49% |
| 2018 Q4 | 10.72 Million EUR | -47.2% |
| 2017 FY | - EUR | -185.48% |
| 2017 Q2 | -28.06 Million EUR | -467.94% |
| 2017 Q3 | 56.19 Million EUR | 300.25% |
| 2017 Q4 | -75.57 Million EUR | -234.49% |
| 2017 Q1 | 7.62 Million EUR | 320.69% |
| 2016 FY | - EUR | 5.43% |
| 2016 Q4 | -3.45 Million EUR | -0.83% |
| 2016 Q3 | -3.42 Million EUR | -6.25% |
| 2016 Q2 | -3.22 Million EUR | 15.94% |
| 2016 Q1 | -3.83 Million EUR | -605.74% |
| 2015 Q2 | -3.5 Million EUR | -6.12% |
| 2015 Q1 | -3.29 Million EUR | -162.49% |
| 2015 FY | - EUR | -496.72% |
| 2015 Q4 | -543.74 Thousand EUR | 84.04% |
| 2015 Q3 | -3.4 Million EUR | 2.66% |
| 2014 Q2 | -3.05 Million EUR | 27.24% |
| 2014 Q3 | -4.81 Million EUR | -57.41% |
| 2014 FY | - EUR | 123.48% |
| 2014 Q1 | -4.2 Million EUR | 63.94% |
| 2014 Q4 | 5.27 Million EUR | 209.63% |
| 2013 Q3 | -3.69 Million EUR | -328.06% |
| 2013 Q4 | -11.66 Million EUR | -215.59% |
| 2013 FY | - EUR | 39.02% |
| 2013 Q1 | -2.09 Million EUR | 63.56% |
| 2013 Q2 | 1.62 Million EUR | 177.19% |
| 2012 Q3 | -7.19 Million EUR | 13.93% |
| 2012 FY | - EUR | -7.59% |
| 2012 Q4 | -5.75 Million EUR | 19.92% |
| 2012 Q1 | -6.14 Million EUR | -73.42% |
| 2012 Q2 | -8.35 Million EUR | -36.03% |
| 2011 Q4 | -3.54 Million EUR | 46.25% |
| 2011 Q3 | -6.58 Million EUR | 0.96% |
| 2011 Q2 | -6.65 Million EUR | -9.73% |
| 2011 FY | - EUR | 48.05% |
| 2011 Q1 | -6.06 Million EUR | 75.18% |
| 2010 FY | - EUR | -39.53% |
| 2010 Q4 | -24.42 Million EUR | -304.2% |
| 2010 Q2 | -6.29 Million EUR | 21.32% |
| 2010 Q1 | -7.99 Million EUR | 4.92% |
| 2010 Q3 | -6.04 Million EUR | 3.94% |
| 2009 Q3 | -9 Million EUR | -35.35% |
| 2009 FY | - EUR | 1.19% |
| 2009 Q4 | -8.41 Million EUR | 6.56% |
| 2009 Q2 | -6.65 Million EUR | 22.37% |
| 2009 Q1 | -8.56 Million EUR | 0.0% |
| 2008 FY | - EUR | 29.65% |
| 2007 FY | - EUR | -131.34% |
| 2006 FY | - EUR | -4.23% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | 251.397% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 103.739% |
| Adocia SA | -22.73 Million EUR | 121.912% |
| Aelis Farma SA | -6.34 Million EUR | 178.477% |
| Biophytis S.A. | -13.8 Million EUR | 136.083% |
| Advicenne S.A. | -6.24 Million EUR | 179.772% |
| genOway Société anonyme | 6.35 Million EUR | 21.569% |
| IntegraGen SA | -52.5 Thousand EUR | 9587.01% |
| Medesis Pharma S.A. | -3.84 Million EUR | 229.548% |
| Neovacs S.A. | -8.44 Million EUR | 158.949% |
| NFL Biosciences SA | -4.04 Million EUR | 223.008% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | -6767.455% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | 273.343% |
| Sensorion SA | -22.31 Million EUR | 122.322% |
| Theranexus Société Anonyme | -7.38 Million EUR | 167.427% |
| TME Pharma N.V. | -5.07 Million EUR | 198.205% |
| Valbiotis SA | -6.95 Million EUR | 171.617% |
| TheraVet SA | -517.33 Thousand EUR | 1062.81% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 126.332% |
| argenx SE | -199.5 Million EUR | 102.497% |
| BioSenic S.A. | -6.79 Million EUR | 173.293% |
| Celyad Oncology SA | -7.76 Million EUR | 164.163% |
| DBV Technologies S.A. | -79.53 Million EUR | 106.263% |
| Galapagos NV | 51.03 Million EUR | 90.24% |
| Genfit S.A. | -28.05 Million EUR | 117.757% |
| GeNeuro SA | -14.31 Million EUR | 134.789% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 133.251% |
| Innate Pharma S.A. | -7.57 Million EUR | 165.729% |
| Inventiva S.A. | -101.84 Million EUR | 104.891% |
| MaaT Pharma SA | -19.74 Million EUR | 125.233% |
| MedinCell S.A. | -20.04 Million EUR | 124.848% |
| Nanobiotix S.A. | -34.01 Million EUR | 114.642% |
| Onward Medical N.V. | -35.23 Million EUR | 114.137% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 212.352% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 121.409% |
| Oxurion NV | -16.72 Million EUR | 129.774% |
| Poxel S.A. | -12.17 Million EUR | 140.898% |
| GenSight Biologics S.A. | -21.73 Million EUR | 122.922% |
| Transgene SA | -27.02 Million EUR | 118.432% |
| Financière de Tubize SA | 184.57 Thousand EUR | -2598.672% |
| UCB SA | 1.26 Billion EUR | 99.607% |
| Valneva SE | -64.51 Million EUR | 107.72% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 117.568% |